-- CD BioGlyco launched its Therapeutic Nucleic Acid Development Platform. The company says the platform combines nucleic acid synthesis and delivery into a single service. Most platforms only handle one or the other, according to CD BioGlyco. "We built this to save researchers time," said Anna, project leader at CD BioGlyco.
The platform was launched to solve three main problems: stability inside the body, getting the drug to the right place, and making sure it actually gets absorbed—that is, bioavailability. For drug manufacturing, CD BioGlyco uses the standard method—solid-phase synthesis. As for drug delivery, they have two tools. One is GalNAc, which targets the liver. The other is LNP, or lipid nanoparticles. (LNPs are what made the Covid mRNA vaccines work.) The company says its platform achieves purity above 95%, and it is designed for both researchers and companies. That means pretty much anyone working on siRNA, mRNA, or antisense drugs can use it.
The platform also supports custom modifications. It can currently produce more than a dozen types of nucleic acid drugs. That includes siRNA for gene silencing, miRNA for gene regulation, and ASO (antisense oligonucleotides). Also available: sgRNA for CRISPR, circular RNA, and several types of mRNA. Researchers can add chemical modification groups—such as phosphorothioate or 2'-O-methyl—to make the drug last longer in the body. CD BioGlyco says its purification process achieves over 95% purity. The process uses high-performance liquid chromatography (HPLC) and tangential flow filtration (TFF), followed by quality control via mass spectrometry (MS) and ultra-performance liquid chromatography (UPLC).
CD BioGlyco says the platform can be used for several types of research. One is vaccine development. The company makes mRNA for that, including self-amplifying RNA. Another is cell therapy. Researchers can engineer cells outside the body using nucleic acids, then put them back in. CAR-T therapies work that way. The platform also supports gene editing—specifically, they produce sgRNA for CRISPR experiments. And for diagnostics? They can build RNA-based sensors to track disease markers. Not every platform does that last one.
CD BioGlyco runs quality checks on everything they make. They use mass spec and UPLC to verify purity and sequence. The platform is CMC-ready, meaning it meets standards drug regulators look for.
Contact Info:
Name: Anna Bryan
Email: Send Email
Organization: CD BioGlyco
Website: https://www.bioglyco.com/
Release ID: 89190412
Google
RSS